Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29999687 | 0.99 | ADRB2 (0.54) | ADRB2SLC6A3ADRB1ADRB3KDM1A | |
| SCHEMBL5898981 | 0.88 | ADRB2 (0.64) | ADRB2ADRB1ADRB3KDM1ADRD2 | |
| SCHEMBL29440266 | 0.88 | ADRB2 (0.64) | ADRB2ADRB1ADRB3KDM1ADRD2 | |
| SCHEMBL5898915 | 0.88 | ADRB2 (0.64) | ADRB2ADRB1ADRB3KDM1ADRD2 | |
| SCHEMBL5898906 | 0.88 | ADRB2 (0.64) | ADRB2ADRB1ADRB3KDM1ADRD2 | |
| Bromide SCHEMBL26186975 | 0.87 | ADRB2 (0.63) | ADRB2ADRB1ADRB3KDM1ADRD2 | |
| Bromide SCHEMBL5898965 | 0.87 | ADRB2 (0.63) | ADRB2ADRB1ADRB3KDM1ADRD2 | |
| Bromide SCHEMBL4249633 | 0.87 | ADRB2 (0.63) | ADRB2ADRB1ADRB3KDM1ADRD2 | |
| Bromide SCHEMBL30596426 | 0.86 | ADRB2 (0.62) | ADRB2ADRB1ADRB3KDM1ADRD2 | |
| SCHEMBL6181835 | 0.83 | KMT2A (0.53) | SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2023177919-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20220387561-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | COSTA RICAN SOCIAL SECURITY FUND / CAJA COSTARRICENSE DE SEGURO SOCIAL CCSS (CR) | 2022-12-08 | — | — | US | disclosed |
| US-20220008519-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | US | disclosed |
| WO-2022008971-A2 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | WO | disclosed |
| US-20210093612-A1 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY | WARSAW ORTHOPEDIC INC (US) | 2021-04-01 | — | — | US | disclosed |
| EP-2077821-B1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | UNIV QUEENSLAND (AU) | 2019-08-14 | — | — | EP | disclosed |
| US-20190125826-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES ASSOCIATED WITH DESMOGLEIN-1 DEFICIENCY | INSERM INSTITUT NAT DE LA SANTE ET DE LA MEDICALE (FR) | 2019-05-02 | — | — | US | disclosed |
| US-20190083464-A1 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY | WARSAW ORTHOPEDIC, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20190076403-A1 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY | WARSAW ORTHOPEDIC, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-03 | — | — | US | disclosed |
| EP-2363122-A1 | Clonidine to treat pain locally | Medtronic, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20100159015-A1 | Systems and Methods to Treat Pain Locally | WARSAW ORTHOPEDIC, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2043625-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | Medtronic, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1781267-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008014066-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | MEDTRONIC, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1781267-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060253100-A1 | Systems and Methods to Treat Pain Locally | MEDTRONIC, INC. (US) | 2006-11-09 | — | — | US | disclosed |
| US-20050271661-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005115455-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | TFAM, AIFM1, MAVS | ADRB2 2961/4885SLC6A3 4325/4885ADRB1 2167/4885 |
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CHAT, PINK1, DBH | ADRB2 3405/4885SLC6A3 23/4885ADRB1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.